CAPR vs PATH
Capricor Therapeutics Inc (CAPR) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Capricor Therapeutics Inc (CAPR) is a biotechnology company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported CAPR revenue for 2024-12-31 was $22.3M. Net income was -$40.5M. Revenue was down 11.5% from 2023-12-31 to 2024-12-31. CAPR currently screens at market cap $1.62B.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
CAPR currently screens at market cap $1.62B. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the CAPR and PATH stock pages for the full models.
Not investment advice.